Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from a comprehensive analysis of the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small cell lung cancer
Findings from the LEAP-004 study
Findings from the STO-5 study
Findings from the TOTEM study
Melphalan flufenamide is a lipophilic derivative of melphalan designed to enhance cell penetration
Primary data from the DETERMINATION study
Data from a final analysis of the KEYNOTE-355 study
Crizotinib received orphan drug designation
Final overall survival results of the POLO study
New indication concerns the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 based regimens
Adjuvant therapies are often approved based on composite, surrogate endpoints with high costs per event averted
Data from a median of 6 years follow-up from the ECHELON-1 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
